PRRT2 and breast cancer: Targeting the nPKC-θ axis reduced the CD44hi/CD24lo CSC population in mesenchymal breast cancer cell lines, consistent with previous studies showing that high PKC-θ expression results in aberrant cell proliferation, migration, and invasion [54,64,66].